AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31987919 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse disorder
Number of subjects: 700
Study 31987919 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent victimization
Number of subjects: 700
Study 31987919 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on strategies (lithium, lamotrigine/carbamazepine, anti-inflammatory drugs)
Number of subjects: 700
Study 30189820 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter over needle (CON) system
Number of subjects: 110
Study 30189820 — intervention group
Group type: COMPARATOR
Intervention: Catheter through needle (CTN) system
Number of subjects: 110
Study 27156655 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule Endoscopy (CE)
Number of subjects: 71
Study 27156655 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 71
Study 24861540 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced labelling
Number of subjects: 66
Study 24861540 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory cues (tones)
Number of subjects: 66
Study 23249635 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed urinary incontinence
Number of subjects: 225
Study 23249635 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe symptoms
Number of subjects: 225
Study 23249635 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress urinary incontinence
Number of subjects: 225
Study 23249635 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate severity of symptoms
Number of subjects: 225
Study 20216318 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary heart disease (CHD) group
Number of subjects: 2491
Study 20216318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrovascular disease (CVD) group
Number of subjects: 2491
Study 20216318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac localization of ischemic event
Number of subjects: 2491
Study 17373638 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg qd
Number of subjects: 632
Study 17373638 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg bid
Number of subjects: 632
Study 17373638 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg qd
Number of subjects: 632
Study 17373638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 632
Study 17373638 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg
Number of subjects: 632
Study 17373638 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 632
Study 15842558 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg tolterodine bid
Number of subjects: 52
Study 15842558 — intervention group
Group type: COMPARATOR
Intervention: 5 mg oxybutynin tid
Number of subjects: 52
Study 12554247 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 microg (low dose)
Number of subjects: 0
Study 12554247 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 100 microg (high dose)
Number of subjects: 0
Study 9527561 — intervention group
Group type: EXPERIMENTAL
Intervention: AAA bone implantation
Number of subjects: 14
Study 9527561 — intervention group
Group type: COMPARATOR
Intervention: Modified Widman flap surgery alone (control)
Number of subjects: 14
Study 7842205 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 12
Study 7842205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2132187 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer from porcine to human insulin
Number of subjects: 108
Study 2132187 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer from bovine to human insulin
Number of subjects: 108
Study 2132187 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 108
Study 74494 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 1026
Study 31920176 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Pest Management (IPM)
Number of subjects: 384
Study 31920176 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 384
Study 31642244 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized intervention through the combination of prenatal and postnatal care
Number of subjects: 341
Study 31642244 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 341
Study 31642244 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized intervention
Number of subjects: 341
Study 28537012 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical treatment
Number of subjects: 40
Study 28537012 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study 25514619 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil-containing lipid emulsions (FO)
Number of subjects: 483
Study 25514619 — intervention group
Group type: COMPARATOR
Intervention: Control lipid emulsions (CO)
Number of subjects: 483
Study 23391196 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14624
Study 23391196 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14624
Study 23391196 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Rivaroxaban and Warfarin
Number of subjects: 14624
Study 20439262 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Navigation System (MNS)
Number of subjects: 31
Study 20439262 — intervention group
Group type: COMPARATOR
Intervention: Standard guidewires
Number of subjects: 31
Study 19656250 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion (20 mg ATP during isoproterenol infusion)
Number of subjects: 88
Study 19656250 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassessment at 30 minutes postisolation
Number of subjects: 88
Study 19656250 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ATP induction and 30 minutes reassessment
Number of subjects: 88
Study 17241411 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 to 40 U BTX‐A
Number of subjects: 79
Study 17241411 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 U BTX‐A
Number of subjects: 79
Study 15010154 — intervention group
Group type: EXPERIMENTAL
Intervention: Knifelight technique
Number of subjects: 26
Study 15010154 — intervention group
Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 26
Study 11396234 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP in patients with pancreatic cancer
Number of subjects: 75
Study 9506661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine treatment
Number of subjects: 0
Study 9506661 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation (suggested)
Number of subjects: 0
Study 8794413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 2.0 g/m2 days 1-3, mesna 400 mg/m2 at 0, 4, 6 h days 1-3, cisplatin 33 mg/m2 days 1-3 with G-CSF 5 micrograms/kg SQ day 4 to post day 11.
Number of subjects: 101
Study 8794413 — intervention group
Group type: COMPARATOR
Intervention: Etoposide 200 mg/m2 days 1-3, cisplatin 35 mg/m2 days 1-3 with G-CSF 5 micrograms/kg SQ day 4 to post day 11.
Number of subjects: 101
Study 2297966 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow injection (mean 0.975 ml/s)
Number of subjects: 100
Study 2297966 — intervention group
Group type: COMPARATOR
Intervention: Rapid injection (mean 2.575 ml/s)
Number of subjects: 100
Study 7270561 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 10 mg and hydrochlorothiazide 25 mg (T/H)
Number of subjects: 19
Study 7270561 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg (HCTZ)
Number of subjects: 19
Study 30785765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold temperature (0 °C) with no active warm-up (CNWU)
Number of subjects: 7
Study 30785765 — intervention group
Group type: COMPARATOR
Intervention: Cold temperature (0 °C) with active warm-up (CWU)
Number of subjects: 7
Study 28494595 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐Coat Plus
Number of subjects: 60
Study 28494595 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliobond
Number of subjects: 60
Study 28494595 — intervention group
Group type: COMPARATOR
Intervention: Both G‐Coat Plus and Heliobond
Number of subjects: 60
Study 25308968 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic radical prostatectomy
Number of subjects: 2506
Study 25308968 — intervention group
Group type: COMPARATOR
Intervention: Open radical prostatectomy
Number of subjects: 2506
Study 23621385 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 seconds inflation time
Number of subjects: 20
Study 23621385 — intervention group
Group type: COMPARATOR
Intervention: 2 minutes inflation time
Number of subjects: 20
Study 21068008 — intervention group
Group type: EXPERIMENTAL
Intervention: L-4F administered by intravenous (IV) infusion for 7 days
Number of subjects: 0
Study 21068008 — intervention group
Group type: EXPERIMENTAL
Intervention: L-4F administered by subcutaneous (SC) injection for 28 days
Number of subjects: 0
Study 21068008 — intervention group
Group type: EXPERIMENTAL
Intervention: L-4F at concentrations of 150, 375, or 1,000 ng/ml added to plasma ex vivo
Number of subjects: 0
Study 19127438 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based mantram intervention
Number of subjects: 93
Study 19127438 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control
Number of subjects: 93
Study 17330282 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized intervention program run by rheumatologists, following detailed proceedings, lasting 12 months.
Number of subjects: 13077
Study 17330282 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 13077
Study 15468020 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-related training (TRT) for low-level subjects
Number of subjects: 12
Study 15468020 — intervention group
Group type: COMPARATOR
Intervention: Progressive resistive exercise (PRE) for low-level subjects
Number of subjects: 12
Study 15468020 — intervention group
Group type: COMPARATOR
Intervention: Progressive resistive exercise (PRE) for high-level subjects
Number of subjects: 12
Study 15468020 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-related training (TRT) for high-level subjects
Number of subjects: 12
Study 11441198 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril at 10 mg/d (n=48)
Number of subjects: 98
Study 11441198 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=50)
Number of subjects: 98
Study 11441198 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril use
Number of subjects: 98
Study 8883531 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol at 270 mg I/ml (IOD-270)
Number of subjects: 99
Study 8883531 — intervention group
Group type: COMPARATOR
Intervention: iohexol at 300 mg I/ml (IOH-300)
Number of subjects: 99
Study 8883531 — intervention group
Group type: EXPERIMENTAL
Intervention: Both iodixanol and iohexol
Number of subjects: 99
Study 1562096 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg i.v. 10 min prior to intubation
Number of subjects: 80
Study 1562096 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg i.m. 30 min prior to intubation
Number of subjects: 80
Study 1562096 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atropine)
Number of subjects: 80
Study 1562096 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (both i.m. and i.v.)
Number of subjects: 80
Study 4056240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of hydrocortisone (300 mg)
Number of subjects: 31
Study 4056240 — intervention group
Group type: COMPARATOR
Intervention: Solvent (control)
Number of subjects: 31
Study 4056240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injections of 20 mg of methylprednisolone, 4 mg of dexamethasone, or 4 mg of betamethasone
Number of subjects: 31
Study 31703707 — intervention group
Group type: EXPERIMENTAL
Intervention: SMG-based health-promoting lifestyles interventions for 7 months
Number of subjects: 350
Study 30390875 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus Rhamnosus
Number of subjects: 42
Study 30390875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 27291327 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D with Telemonitoring (TM)
Number of subjects: 191
Study 27291327 — intervention group
Group type: COMPARATOR
Intervention: CRT-D with traditional ambulatory monitoring (control group)
Number of subjects: 191
Study 24531833 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 concealed information test with 33, 66, and 100 trial averages
Number of subjects: 0
Study 24531833 — intervention group
Group type: COMPARATOR
Intervention: 3-stimulus protocol
Number of subjects: 0
Study 24531833 — intervention group
Group type: COMPARATOR
Intervention: Complex trial protocol
Number of subjects: 0
Study 22734581 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol i.v. 1 g
Number of subjects: 24
Study 22734581 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol i.v. 2 g
Number of subjects: 24
Study 22734581 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone i.v. (0.1 mg/kg)
Number of subjects: 24
Study 19841862 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) for 6 weeks
Number of subjects: 30
Study 19841862 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 30
Study 17564290 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 100
Study 17564290 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibitors
Number of subjects: 100
Study 17564290 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 100
Study 17564290 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smoking status
Number of subjects: 100
Study 17564290 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol levels
Number of subjects: 100
Study 16096182 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate lotion
Number of subjects: 192
Study 16096182 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate emollient cream
Number of subjects: 192
Study 16096182 — intervention group
Group type: COMPARATOR
Intervention: Vehicle lotion
Number of subjects: 192
Study 12322819 — intervention group
Group type: COMPARATOR
Intervention: Fluid status assessment using tracer dilution techniques (ECV, TBW, PV)
Number of subjects: 41
Study 12322819 — intervention group
Group type: COMPARATOR
Intervention: Fluid status assessment (TBW:BSA, ECV:BSA, PV:BSA)
Number of subjects: 41
Study 12322819 — intervention group
Group type: COMPARATOR
Intervention: Arterial distensibility assessment of the common carotid artery
Number of subjects: 41
Study 12322819 — intervention group
Group type: COMPARATOR
Intervention: ECV assessment
Number of subjects: 41
Study 12322819 — intervention group
Group type: COMPARATOR
Intervention: Arterial distensibility assessment
Number of subjects: 41
Study 12322819 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory BP measurements
Number of subjects: 41
Study 12322819 — intervention group
Group type: COMPARATOR
Intervention: Office BP measurements
Number of subjects: 41
Study 10419988 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA Step I diet with targeted reduction in energy intake of approximately 1000 kJ/d for 6 months
Number of subjects: 6
Study 7677684 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopped smoking
Number of subjects: 197
Study 7677684 — intervention group
Group type: COMPARATOR
Intervention: Continued to smoke
Number of subjects: 197
Study 2013244 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 0.5 g plus amikacin 500 mg i.v. 2 h before surgery and the same doses per 8 or 12 h for 2 days postoperatively (Group A)
Number of subjects: 50
Study 2013244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole 1 g by intravenous infusion plus ceftriaxone 2 g i.v. 2 h before surgery and the same doses per 24 h for 2 days postoperatively (Group B)
Number of subjects: 50
Study 2013244 — intervention group
Group type: COMPARATOR
Intervention: Ornidazole plus ceftriaxone
Number of subjects: 50
Study 7106840 — intervention group
Group type: EXPERIMENTAL
Intervention: Spleen exposure to ultrasound (2.0 mW/m2, 3.5 MHz, 5 minutes)
Number of subjects: 41
Study 7106840 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 41
Study 31233220 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J pouch
Number of subjects: 379
Study 31233220 — intervention group
Group type: COMPARATOR
Intervention: Straight colorectal anastomosis
Number of subjects: 379
Study 28872774 — intervention group
Group type: COMPARATOR
Intervention: No Drain Placement (ND)
Number of subjects: 189
Study 28872774 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Drain Placement (PD)
Number of subjects: 189
Study 27557121 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BVZ) + Temozolomide (TMZ) for seven weeks followed by radiotherapy
Number of subjects: 40
Study 27557121 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BVZ) + Temozolomide (TMZ)
Number of subjects: 40
Study 27557121 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ) for eight weeks followed by concomitant radiotherapy and TMZ
Number of subjects: 40
Study 24723147 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (mean dose 5.1 ± 2.3 mg/day)
Number of subjects: 15
Study 24723147 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study 22287221 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 8 Gy doses of external beam radiation
Number of subjects: 7
Study 22287221 — intervention group
Group type: COMPARATOR
Intervention: No radiation (control group)
Number of subjects: 7
Study 20481041 — intervention group
Group type: EXPERIMENTAL
Intervention: Imunofan combined with basic therapy
Number of subjects: 69
Study 20481041 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 69
Study 17277350 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Angioplasty
Number of subjects: 7518
Study 17277350 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 7518
Study 15012924 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month aerobic program above standard treatment
Number of subjects: 34
Study 15012924 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without special advice for exercise
Number of subjects: 34
Study 11603100 — intervention group
Group type: EXPERIMENTAL
Intervention: Keto acids/amino acids (KA) supplementation at a dosage of 100 mg/kg/day
Number of subjects: 38
Study 11603100 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (Control Group II)
Number of subjects: 38
Study 9587722 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-Midazolam (0.125% bupivacaine 0.75 mL kg‐1 with 0.5% midazolam 50 micrograms kg‐1)
Number of subjects: 60
Study 9587722 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-Morphine (0.125% bupivacaine 0.75 mL kg‐1 with 1% morphine chlorhydrate 0.05 mg kg‐1)
Number of subjects: 60
Study 9587722 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (0.125% bupivacaine 0.75 mL kg‐1)
Number of subjects: 60
Study 7985754 — intervention group
Group type: EXPERIMENTAL
Intervention: Acridine orange staining method
Number of subjects: 49
Study 7985754 — intervention group
Group type: COMPARATOR
Intervention: Thick blood film
Number of subjects: 49
Study 2907749 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 8
Study 2907749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31004523 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral function intervention only
Number of subjects: 83
Study 31004523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention only
Number of subjects: 83
Study 31004523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral function plus nutritional intervention
Number of subjects: 83
Study 28993388 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic medication reminder app group
Number of subjects: 156
Study 28993388 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced medication reminder app group
Number of subjects: 156
Study 28993388 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 156
Study 28993388 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 156
Study 25778987 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of American ginseng (Panax quinquefolius)
Number of subjects: 52
Study 25778987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 22270179 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking for 1 hour
Number of subjects: 63
Study 22270179 — intervention group
Group type: COMPARATOR
Intervention: Bed rest for 1 hour
Number of subjects: 63
Study 22270179 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour labor check evaluation
Number of subjects: 63
Study 20078486 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit training to avoid alcohol (avoid-alcohol condition)
Number of subjects: 42
Study 20078486 — intervention group
Group type: COMPARATOR
Intervention: Implicit training to approach alcohol (approach-alcohol condition)
Number of subjects: 42
Study 20078486 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic action tendencies assessed with the AAT and IAT
Number of subjects: 42
Study 20078486 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective craving assessment
Number of subjects: 42
Study 16169582 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive follow-up guidance system
Number of subjects: 2250
Study 16169582 — intervention group
Group type: COMPARATOR
Intervention: Selective follow-up guidance system
Number of subjects: 2250
Study 12076867 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 99
Study 12076867 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 99
Study 10457386 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline combined with levodopa and benserazide
Number of subjects: 163
Study 10457386 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with levodopa and benserazide
Number of subjects: 163